Related Experiment Videos
[Present strategy for new drug development in the USA]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1994
Summary
Developing new anticancer drugs is crucial for improving patient outcomes. Nationally funded cancer centers in the U.S. play a vital role in early-phase clinical trials for novel therapeutics.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Context:
- Advancing cancer treatment necessitates the development of novel anticancer drugs.
- Nationally supported organizations are critical for conducting high-cost, experimental, and ethical clinical trials.
- The National Cancer Institute (NCI) in the U.S. has established six specialized cancer centers for Phase I drug evaluation.
Purpose:
- To highlight the role of national organizations in early-phase anticancer drug trials.
- To describe the structure and function of Phase I clinical trial centers.
- To acknowledge the international landscape of new drug development, including harmonization and competition.
Summary:
- The U.S. National Cancer Institute (NCI) supports six cancer centers dedicated to Phase I trials for new drug evaluation.
- These centers, such as the Cancer Therapy and Research Center (CTRC) and the Jonsson Comprehensive Cancer Center (JCCC), evaluate over 10 new drugs annually.
- Multidisciplinary teams, including physicians, nurses, pharmacologists, and investigators, drive these evaluations.
Impact:
- These centers are pivotal in advancing the pipeline of innovative cancer therapies.
- The infrastructure supports rigorous evaluation of experimental drugs, potentially leading to improved patient survival.
- Understanding the international context is key for future collaborative and competitive drug development efforts.